

The aim of this study was to investigate a potential antihypertensive and antihyperglycemic effects of Ginseng Radix palva (GRP) and Ginseng Radix Alba (GRA) in spontaneously hypertensive rat (SHR) injected with streptozotocin (STZ). Animals were divided into four groups containing 6 rats each as follows : Group 1, SHR drinking a tap water (hypertensive control) ; Group 2, SHR-STZ (hypertensive and hyperglycemic control) ; Group 3, SHR-STZ administered with 500 mg/kg/day of GRA ; Group 4, SHR-STZ administered with 500 mg/kg/day of GRP. Ginseng Radices were administered to 6 week-old SHR-STZ rats for 4 weeks and blood pressure (SBP, DBP), heart rate and blood glucose were determined at 2 weekly. After 4 weeks, serum creatinine, urinary albumin excretion(UAE) and glomerular TGF-beta mRNA and protein levels were compared between experimental groups. Ginseng Radices treated groups improved hypertensive and hyperglycemic abnormalities when compared to the SHR-STZ control.

[PA1-37] [ 04/20/2001 (Fri) 10:30 - 11:30 / Hall 4 ]

### **G protein and MAP kinase mediates sphingosylphosphorylcholine-induced feline ileal smooth muscle cell contraction.**

Lee TS<sup>o</sup>, Shin CY, Lee YP, Park SY, Kim TH, Kang HY, Huh IH and Sohn UD

Department of Pharmacology, College of Pharmacy, Chung Ang University

It has been shown that sphingosylphosphorylcholine (SPC) produced pertussis toxin sensitive contraction of feline ileal smooth muscle cells (Lee et al., 1999). We studied further mechanism of the contraction that might involve the activation of a certain Gi protein and phospholipase and kinases-dependent pathway using Western blot and GTP $\gamma$ S binding techniques. Western blotting using G protein antibody revealed that subtypes of Gi1, Gi3 and Go existed in feline ileum. Gi3 antibody treatment in permeabilized single cells isolated with collagenase decreased SPC-induced contraction. In addition, [<sup>35</sup>S]GTP $\gamma$ S binding study showed that Gi3 subtype activated significantly after SPC treatment, because SPC elevated the binding of Gi3 protein with [<sup>35</sup>S]GTP $\gamma$ S. To examine the relation of MAP kinase and SPC-induced contraction, we pretreated PD 98059, MEK inhibitor, and SB202190, p38 MAP kinase inhibitor. The contraction was blocked by PD 98059, but not by SB 202190. PKC inhibitor, chelerythrine, and PLC inhibitor, neomycin also decreased the contraction. However, co-treatment of PD98059 and chelerythrine showed no significant difference. When we examined MAP kinase activation using phospho MAP kinase antibody, SPC increased the band of phospho-MAP kinase. We suggest that SPC-induced contraction is mediated via pathway involving Gi3 protein coupled to PLC, resulting in the activation of PKC and p42/44 MAP kinase in feline ileal smooth muscle cells.

[PA1-38] [ 04/20/2001 (Fri) 10:30 - 11:30 / Hall 4 ]

### **The effect of extremely low frequency magnetic fields on NO levels in brain regions of rats**

Jeong JH<sup>o</sup>, Sung JH, Kum C, Kim JS, Kim HR, JH Kim, HJ Song, Huh IH, Sohn UD

Department of Pharmacology, College of Pharmacy, Chung Ang University

It has been shown that the extremely low frequency magnetic fields (MFs) produce the biological effects in the brains. MFs affect nitric oxide (NO) production, which plays a major role in neurotransmission and pathogenesis in the brain. To confirm the relevance of NO and MFs in the brain, we investigated the concentration of NO in various brain areas (cortex, cerebellum, hippocampus thalamus and striatum) of rats following exposure to MFs. Rats were exposed for 2 or 5 days to MFs (60Hz, 10, 15, 20 gauss, G) or sham in a laboratory exposure facility. 20 G MFs exposure for 2 or 5 days caused a continuous increase in NO release of hippocampus, thalamus and striatum, whereas no changes were obtained in cerebellum and cortex. Low strength in MFs did not alter the

level of NO in brains. The expression of NOS was not also influenced by MFs exposure. These results suggest that MFs exposure can affect NO levels in rat brain. Further studies remains to be performed to confirm the definite relevance of MFs and NO system.

Poster Presentations – Field A2. Therapeutics

[PA2-1] [ 04/20/2001 (Fri) 10:30 – 11:30 / Hall 4 ]

**Neuroprotective effect of KR-31378 in cortical cell culture and in brain ischemia-reperfusion model**

Kim SO<sup>o</sup>, Cho IS, Gu HG, Hwang GS, Lee DH, Hong L and Yoo SE

AgroPharma Research Institute, Dongbu Hannong Chemical Co., Korea Research Institute of Chemical Technology

Despite of considerable research efforts for the development of neuroprotective agents to save neurons from the biochemical and metabolic outcomes of ischemic brain injury, most of neuroprotective agents studied so far have shown their lack of clinical efficacy. This failure is probably due to the complex and multifactorial nature of ischemic brain injury. Thus, it is probably necessary to protect damages from two key events, ischemic injury and reperfusion injury.

Inhibition of lipid peroxidation induced by reactive oxygen species and stabilization of membrane have both been proposed as neuroprotective strategies in stroke. In this context, KR-31378, a novel benzopyran derivatives with N-cyanoguanidine group were synthesized as a new therapeutic strategy for neuroprotection. Possessing both anti-oxidant and potassium channel modulating activities without vasorelaxation activity, it has shown to protect cultured rat cortex neurons against oxidative injury induced by FeSO<sub>4</sub> and by hypoxia-reperfusion in vitro. Also, Treatment with KR-31378 significantly reduced brain damage in transient ischemia rat model, demonstrated by reduced infarct size, edema and mortality. Furthermore, treatment with KR-31378 starting up to 2h after reperfusion maintained its neuroprotective effect. All these results indicate that KR-31378 represents a potentially useful therapeutic agent for the treatment of ischemic/reperfusion brain injury.

[PA2-2] [ 04/20/2001 (Fri) 10:30 – 11:30 / Hall 4 ]

**Study on toxicity and in vitro cytotoxicity of ID6105 (Hyribicin), A new anticancer agent**

Ryu Jung Su, Hong-Sub Lee, Hang-Sub Kim<sup>1</sup>, Tae-Yong Kim, Jung-Jun Lee<sup>1</sup>, Kang Jong Gu<sup>2</sup>, Kee-Won Kim

Research Laboratories, Ildong Pharmaceutical Co., Ltd., Korea Research Institute of Bioscience and Biotechnology 1, College of veterinary medicine, ChungBuk university<sup>2</sup>

New anthracyclines, ID6105 (Hyribicin) and ID6101 (Aclacinomycin X), were isolated from *Streptomyces galilaeus* ATCC 3113 containing dnrF. The in vitro cytotoxicity of ID6105 and ID6101 was tested on murine and human cancer cell lines in comparison with adriamycin and aclacinomycin A by SRB assay. The acute toxicity of these compounds for mouse was also tested. As a result, the ID6105 was 10~100 times more cytotoxic than adriamycin, and 3 ~10 times than